Suggested Readings

Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC) +dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG.

Bosch B, Akpomiemie G, Chandiwana N, et al. Clin Infect Dis. 2022;ciac949.

HIV-related cardiovascular diseases: the search for a unifying hypothesis.

Dominick L, Midgley N, Swart LM, et al. Am J Physiol Heart Circ Physiol. 2020;318(4):H731-H746.

Type 2 diabetes prevalence and its risk factors in HIV: a cross-sectional study.

Duncan AD, Goff LM, Peters BS. PLoS One. 2018;13(3):e0194199.

Class of antiretroviral drugs and the risk of myocardial infarction.

DAD Study Group. N Engl J Med. 2007;356(17):1723-1735.

Pitavastatin to prevent cardiovascular disease in HIV infection.

Grinspoon SK, Fitch KV, Zanni MV, et al; REPRIEVE Investigators. N Engl J Med. 2023;389(8):687-699.

Markers of renal disease and function are associated with systemic inflammation in HIV infection.

Gupta SK, Kitch D, Tierney C, et al; AIDS Clinical Trials Group Study A5224s Team. HIV Med. 2015;16(10):591-598.

Interconnection between cardiovascular, renal and metabolic disorders: a narrative review with a focus on Japan.

Kadowaki T, Maegawa H, Watada H, et al. Diabetes Obes Metab. 2022;24(12):2283-2296.

The impact of unconscious bias in healthcare: how to recognize and mitigate it.

Marcelin JR, Siraj DS, Victor R, Kotadia S, Maldonado YA. J Infect Dis. 2019;220(220 suppl 2):S62-S73.

Treatment adherence mediates the relationship between HIV-related stigma and health-related quality of life.

Onu DU. AIDS Care. 2021;33(10):1335-1339.

Management of hypertension in chronic kidney disease.

Pugh D, Gallacher PJ, Dhaun N. Drugs. 2019;79(4):365-379.

Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.

Sax PE, Erlandson KM, Lake JE, et al. Clin Infect Dis. 2020;71(6):1380-1390.

Impact of integrase inhibitors on cardiovascular disease events in people with HIV starting antiretroviral therapy.

Surial B, Chammartin F, Damas J, et al; Swiss HIV Cohort Study. Clin Infect Dis. 2023;ciad286. [Epub ahead of print]

Linked Resources

Additional HIV-Related CME/CE Activities

Bridge HIV: Building Bridges to Reach People with HIV Toward the Goal of Re-engagement in Care

The HIV Journey: Staying the Course Through Critical Junctions in Care

Emerging Issues in HIV Management: Answers to Pharmacists' Common Questions

Clinical Practice Guidelines

Standard of Care in Diabetes – 2023

ElSayed NA, et al. Diabetes Care. 2023:45(suppl 1):S1-S291.

Characteristics, prevention, and management of cardiovascular disease in people living with HIV: A scientific statement from the American Heart Association.

Feinstein MJ, Hsue PY, Benjamin LA, et al. Circulation. 2019;140(2):e98-e124.

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA Panel.

Gandhi RT, Bedimo R, Hoy JF, et al. JAMA. 2023;329(1):63-84.

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Grundy SM, Stone NJ, Bailey AL, et al. Circulation. 2019;139(25):e1046-e1081.

Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association.

Joseph JJ, Deedwania P, Acharya T, et al; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; and Council on Hypertension. Circulation. 2022;145(9):e722-e759.

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. Eur Heart J. 2020;41(1):111-188.

Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.

US Department of Health and Human Services

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Whelton PK, Carey RM, Aronow WS, et al. Hypertension. 2018;71(6):e13-e115.

ASCVD Risk Estimator Plus.

American College of Cardiology.

Motivational interviewing and HIV: a guide for navigators.

National Minority AIDS Council.

SAMHSA’s Concept of Trauma and Guidance for a Trauma-Informed Approach.

Substance Abuse and Mental Health Services Administration (SAMHSA).

Patient and Caregiver Resources

AIDSMap Resources

NAM Publications

Resources for persons living with HIV

Centers for Disease Control and Prevention

HIV resources

National Institutes of Health

Related activities

Putting Together Clues in HIV, CVD, T2D, and CKD

Escaping Management Mishaps

Faculty: David A. Wohl, MD; Laura Waters, MD, FRCP
Release: 10/18/2023
Expiration: 10/18/2024